Patent ID: 9603911
Date: 2017-03-28
CPC Classifications: A61K,A61P,C07K,C12N,C12Y

Claim:
1. A modified sarcin polypeptide comprising at least one mutation as compared to a wild type α-sarcin polypeptide having the amino acid sequence of SEQ ID NO:1, wherein the at least one mutation is at one or more of amino acids D9, Q10, P13, T15, N16, or Y18 of the wild type α-sarcin polypeptide and is within a first T cell epitope of the wild type α-sarcin polypeptide and/or is at one or more of amino acids I134, K139, E140, or Q142 of the wild type α-sarcin polypeptide and is within a second T cell epitope of the wild type α-sarcin polypeptide, wherein the first T cell epitope consists of the amino acid sequence of SEQ ID NO:6, and the second T cell epitope consists of the amino acid sequence of SEQ ID NO:4, and wherein the modified sarcin polypeptide inhibits protein synthesis and elicits a reduced T cell response as compared to the wild type α-sarcin polypeptide, wherein the inhibition of protein synthesis is measured using an in vitro transcription and translation assay (IVTT).